Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites.

ABSTRACT: (1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal

SUBMITTER: Hosui A 

PROVIDER: S-EPMC7830941 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature